Fig. 3From: Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension studyPercentages of patients using C1-INH(SC) who demonstrated minimal clinically important difference (MCID) improvements from baseline to end-of-study. C1-INH(SC) subcutaneous C1-inhibitor, EQ-5D European Quality of Life-5 Dimensions Questionnaire, HADS Hospital Anxiety and Depression Scale, TSQM Treatment Satisfaction Questionnaire for Medication, WPAI Work Productivity and Activity Impairment QuestionnaireBack to article page